# Diabetes Therapy to Improve BMI and Lung Function in CF

> **NCT00072904** · PHASE3 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 108 (actual)

## Conditions studied

- Cystic Fibrosis
- Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Asparte
- **DRUG:** Repaglinide

## Key facts

- **NCT ID:** NCT00072904
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2012-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072904, "Diabetes Therapy to Improve BMI and Lung Function in CF". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00072904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*